Needham lowered the firm’s price target on Merit Medical (MMSI) to $90 from $101 and keeps a Buy rating on the shares after it is better than expected Q1 earnings and revenue. The company continues to execute well on its strategy, and the firm anticipates sustained strong revenue growth, margin improvement, and free cash flow, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target lowered to $80 from $100 at BofA
- Analyst Reiterates Buy on Merit Medical Systems as Strong Q1 Results and Cash Generation Offset Growth Deceleration, Trims Price Target to $90 on Sector Multiple Compression
- Steed Maintains Hold on Balanced Risk-Reward, Cutting Price Target to $80 Despite Solid Q1 Beat and Slight Guidance Raise
- Merit Medical price target lowered to $85 from $90 at Canaccord
- Merit Medical Earnings Call Highlights Growth Amid Headwinds